产品
编 号：F622086
分子式：C83H117N23O18S2.xC2HF3O2
分子式：C83H117N23O18S2.xC2HF3O2
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1789738-04-0
产品详情
生物活性：
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
体内研究：
AMY-101可改善自然慢性牙周炎NHPs的牙周状况。AMY-101可诱导长效抗炎作用。 AMY-101 (4 mg/kg 体重，皮下注射。每 24 小时一次，共 28 天) 导致 PPD 显著和持久减少，PPD 是衡量组织破坏的指标。 AMY-101 (Cp40，1 mg/kg，sc，每 12 小时注射一次，每天一次，7 或 14 天) 减轻 UUO 诱导的肾脏纤维化和炎性细胞浸润纤维化。Animal Model:Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:Does not cause irritation in healthy gingiva.
Animal Model:UUO and sham-operated mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
体内研究：
AMY-101可改善自然慢性牙周炎NHPs的牙周状况。AMY-101可诱导长效抗炎作用。 AMY-101 (4 mg/kg 体重，皮下注射。每 24 小时一次，共 28 天) 导致 PPD 显著和持久减少，PPD 是衡量组织破坏的指标。 AMY-101 (Cp40，1 mg/kg，sc，每 12 小时注射一次，每天一次，7 或 14 天) 减轻 UUO 诱导的肾脏纤维化和炎性细胞浸润纤维化。Animal Model:Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:Does not cause irritation in healthy gingiva.
Animal Model:UUO and sham-operated mice.
Dosage:1 mg/kg.
Administration:Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备